Cancer Stem Cells Market Report 2026

The cancer stem cells market size has grown rapidly in recent years. It will grow from $3.24 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advances in stem cell biology research, identification of cancer stem cell populations, growth in oncology research funding, expansion of preclinical cancer models, rising academic-industry collaborations.

The cancer stem cells market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for durable cancer therapies, rising investment in targeted oncology research, expansion of personalized cancer treatment strategies, growing focus on metastasis prevention, increasing integration of csc research in clinical oncology. Major trends in the forecast period include increasing focus on targeting therapy-resistant cancer cells, rising research on csc-specific pathways, growing development of csc biomarkers, expansion of translational and clinical csc research, enhanced integration of csc models in drug discovery.

The increasing demand for personalized medicine is expected to drive the growth of the cancer stem cells market going forward. Personalized medicine refers to treatment strategies designed according to a patient’s genetic profile, tumor biology, and individual response patterns to achieve greater efficacy and reduced side effects. The demand for personalized medicine is rising due to the growing availability and affordability of genomic sequencing technologies, which are increasingly applied in oncology research and clinical practice. Personalized medicine targets cancer stem cells (CSCs) by tailoring therapies to the specific molecular and genetic features of a patient’s tumor. Tumors are analyzed for unique mutations, signaling pathways, and surface markers in their CSC populations, enabling clinicians to select treatments that inhibit critical pathways. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for rare disease patients in 2023, up from six approvals in 2022. Therefore, the rising demand for personalized, precise treatment solutions is driving the growth of the cancer stem cells market.

Major companies operating in the cancer stem cells market are focusing on technological innovations such as pre-analytical immunomagnetic sorting systems to improve cell enrichment and enhance diagnostic accuracy. Pre-analytical immunomagnetic sorting systems are advanced tools that utilize magnetic particles coated with antibodies to isolate specific cancer stem cell populations from complex biological samples, improving sensitivity and reproducibility in downstream analyses. For instance, in March 2024, STEMCELL Technologies, a Canada-based biotechnology company, launched the EasySep Human Bone Marrow CD138 Positive Selection Kit. This kit is the first hematopoietic cell enrichment product to receive FDA de novo classification as a Class II in vitro diagnostic device. It isolates CD138+ plasma cells from bone marrow samples to improve detection of multiple myeloma-related abnormalities, ensuring higher sensitivity, reproducibility, and diagnostic precision, ultimately enhancing patient outcomes in multiple myeloma care. The product strengthens the pre-analytical stage of cancer diagnostics by delivering high-purity cell populations for more reliable downstream testing.

In March 2023, Sona Nanotech Inc., a Canada-based nanotechnology and life sciences company, acquired Siva Therapeutics Inc. for $2 million. Through this acquisition, Sona Nanotech aims to accelerate the development of Targeted Hyperthermia Therapy (THT) for colorectal cancer by combining Siva’s photothermal treatment platform with its proprietary biocompatible gold nanorods. This integration enables minimally invasive procedures that stimulate immune response, reduce tumor size, and improve drug delivery across multiple cancer types. Siva Therapeutics Inc. is a US-based biotechnology company specializing in photothermal cancer therapies using gold nanorod-based heat delivery systems.

Major companies operating in the cancer stem cells market are MacroGenics Inc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Lonza Group AG, A. Menarini Industrie Farmaceutiche Riunite S.r.l., Bio-Techne Corporation, Zymeworks Inc., Kura Oncology Inc., GeneTex Inc., YZY Biopharma Co. Ltd., Abnova Taiwan Corporation, BioView Ltd., ScienCell Research Laboratories Inc., Boster Biological Technology Co. Ltd., AAT Bioquest Inc., Celprogen Inc., Actinium Pharmaceuticals Inc., OncoMed Pharmaceuticals Inc., Fate Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the cancer stem cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer stem cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cancer stem cells market by increasing costs of imported laboratory reagents, cell culture systems, analytical instruments, sequencing tools, and research consumables. Research institutions and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher research infrastructure costs. These tariffs are raising research expenses and slowing experimental timelines. However, they are also encouraging local production of research consumables, regional supplier ecosystems, and domestic investment in cancer research capabilities.

The cancer stem cells market research report is one of a series of new reports that provides cancer stem cells market statistics, including cancer stem cells industry global market size, regional shares, competitors with a cancer stem cells market share, detailed cancer stem cells market segments, market trends and opportunities, and any further data you may need to thrive in the cancer stem cells industry. This cancer stem cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer stem cells (CSCs) are a small subpopulation of cells within a tumor that possess stem cell-like characteristics, including the ability to self-renew and differentiate into various cell types that make up the bulk of the tumor. They are believed to play a critical role in tumor initiation, growth, metastasis, and recurrence, largely because of their resistance to conventional therapies such as chemotherapy and radiation.

The primary types of cancer stem cells are solid tumor stem cells, hematopoietic stem cells, breast cancer stem cells, colorectal cancer stem cells, brain cancer stem cells, and leukemia stem cells. In many solid organ cancers, a small population of cancer stem cells sustains tumor growth, exhibits self-renewal, and possesses the ability to regenerate the tumor’s cellular diversity, thereby contributing to treatment resistance and recurrence. The various cancer forms involved include breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and other cancers, which involve cancerous stem cells (CSCs) and the stem cell-based cancer therapy mode of action. The research types involved are basic research, clinical research, preclinical research, and translational research, serving pharmaceutical and biotechnology companies, research and academic institutions, hospitals and laboratories, and contract research organizations (CROs).

The cancer stem cells market includes of revenues earned by entities by providing services such as biomarker identification, preclinical testing, clinical trial support, cell characterization and therapeutic development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.